|
1
|
Bussolino F, Mantovani A and Persico G:
Molecular mechanisms of blood vessel formation. Trends Biochem Sci.
22:251–256. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li W, Li J, Ashok M, et al: A
cardiovascular drug rescues mice from lethal sepsis by selectively
attenuating a late-acting proinflammatory mediator, high mobility
group box 1. J Immunol. 178:3856–3864. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang AM, Sha SH, Lesniak W and Schacht J:
Tanshinone (Salviae miltiorrhizae extract) preparations attenuate
aminoglycoside-induced free radical formation in vitro and
ototoxicity in vivo. Antimicrob Agents Chemother. 47:1836–1841.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Su CC and Lin YH: Tanshinone IIA
downregulates the protein expression of ErbB-2 and upregulates
TNF-α in colon cancer cells in vitro and in vivo. Int J Mol Med.
22:847–851. 2008.PubMed/NCBI
|
|
5
|
Su CC: Tanshinone IIA potentiates the
efficacy of 5-FU in Colo205 colon cancer cells in vivo through
downregulation of P-gp and LC3-II. Exp Ther Med. 3:555–559.
2012.PubMed/NCBI
|
|
6
|
Liu F, Yu G, Wang G, et al: An
NQO1-initiated and p53-independent apoptotic pathway determines the
anti-tumor effect of tanshinone IIA against non-small cell lung
cancer. PLoS One. 7:e421382012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Somani RR and Bhanushali UV: Targeting
angiogenesis for treatment of human cancer. Indian J Pharm Sci.
75:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Welti J, Loges S, Dimmeler S and Carmeliet
P: Recent molecular discoveries in angiogenesis and antiangiogenic
therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim KJ, Li B, Winer J, et al: Inhibition
of vascular endothelial growth factor-induced angiogenesis
suppresses tumour growth in vivo. Nature. 362:841–844. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Plate KH, Breier G, Weich HA and Risau W:
Vascular endothelial growth factor is a potential tumour
angiogenesis factor in human gliomas in vivo. Nature. 359:845–848.
1992. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang Y, Wang F, Feng J, Yang D, Yang X and
Yan X: Knockdown of CD146 reduces the migration and proliferation
of human endothelial cells. Cell Res. 16:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang T, Zhuang J, Duan H, et al: CD146 is
a coreceptor for VEGFR-2 in tumor angiogenesis. Blood.
120:2330–2339. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang P, Luo Y, Duan H, et al: MicroRNA 329
suppresses angiogenesis by targeting CD146. Mol Cell Biol.
33:3689–3699. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fanjul-Fernández M, Folgueras AR, Cabrera
S and López-Otín C: Matrix metalloproteinases: evolution, gene
regulation and functional analysis in mouse models. Biochim Biophys
Acta. 1803:3–19. 2010. View Article : Google Scholar
|
|
15
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar
|
|
16
|
Tsai MY, Yang RC, Wu HT, Pang JH and Huang
ST: Anti-angiogenic effect of tanshinone IIA involves inhibition of
matrix invasion and modification of MMP-2/TIMP-2 secretion in
vascular endothelial cells. Cancer Lett. 310:198–206. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deryugina EI and Quigley JP: Pleiotropic
roles of matrix metalloproteinases in tumor angiogenesis:
contrasting, overlapping and compensatory functions. Biochim
Biophys Acta. 1803:103–120. 2010. View Article : Google Scholar :
|
|
18
|
Won SH, Lee HJ, Jeong SJ, et al:
Tanshinone IIA induces mitochondria dependent apoptosis in prostate
cancer cells in association with an inhibition of phosphoinositide
3-kinase/AKT pathway. Biol Pharm Bull. 33:1828–1834. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiao JW and Wen F: Tanshinone IIA acts via
p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and
lung-resistance protein in cisplatin-resistant ovarian cancer
cells. Oncol Rep. 25:781–788. 2011.
|
|
20
|
Baudin B, Bruneel A, Bosselut N and
Vaubourdolle M: A protocol for isolation and culture of human
umbilical vein endothelial cells. Nat Protoc. 2:481–485. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burbridge MF and West DC: Rat aortic ring:
3D model of angiogenesis in vitro. Methods Mol Med. 46:185–204.
2001.
|
|
22
|
Yi T, Cho SG, Yi Z, et al: Thymoquinone
inhibits tumor angiogenesis and tumor growth through suppressing
AKT and extracellular signal-regulated kinase signaling pathways.
Mol Cancer Ther. 7:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cross MJ, Dixelius J, Matsumoto T and
Claesson-Welsh L: VEGF-receptor signal transduction. Trends Biochem
Sci. 28:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo ZY and Cao BL: Advances of VEGF
related molecular promoting tumor angiogenesis and targeting
therapy. Zhonghua Bing Li Xue Za Zhi. 39:282–284. 2010.(In
Chinese). PubMed/NCBI
|
|
25
|
Kaspi E, Guillet B, Piercecchi-Marti MD,
et al: Identification of soluble CD146 as a regulator of
trophoblast migration: potential role in placental vascular
development. Angiogenesis. 16:329–342. 2013. View Article : Google Scholar
|
|
26
|
Hua H, Li M, Luo T, Yin Y and Jiang Y:
Matrix metalloproteinases in tumorigenesis: an evolving paradigm.
Cell Mol Life Sci. 68:3853–3868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang JD and Zhang Y: Interregulation of
VEGF/R endostatin and MMP in the angiogenesis of hematologic
malignancies--review. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
13:1145–1150. 2005.(In Chinese).
|
|
28
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shan YF, Shen X, Xie YK, et al: Inhibitory
effects of tanshinone II-A on invasion and metastasis of human
colon carcinoma cells. Acta Pharmacol Sin. 30:1537–1542. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuxian X, Feng T, Ren L and Zhengcai L:
Tanshinone II-A inhibits invasion and metastasis of human
hepatocellular carcinoma cells in vitro and in vivo. Tumori.
95:789–795. 2009.
|
|
31
|
Los M, Roodhart JM and Voest EE: Target
practice: lessons from phase III trials with bevacizumab and
vatalanib in the treatment of advanced colorectal cancer.
Oncologist. 12:443–450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tian S, Quan H, Xie C, et al: YN968D1 is a
novel and selective inhibitor of vascular endothelial growth factor
receptor-2 tyrosine kinase with potent activity in vitro and in
vivo. Cancer Sci. 102:1374–1380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Claesson-Welsh L and Shibuya M: VEGF
receptor signal transduction. Methods Enzymol. 443:261–284. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan X, Lin Y, Yang D, et al: A novel
anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and
tumor growth. Blood. 102:184–191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shaheen RM, Davis DW, Liu W, et al:
Antiangiogenic therapy targeting the tyrosine kinase receptor for
vascular endothelial growth factor receptor inhibits the growth of
colon cancer liver metastasis and induces tumor and endothelial
cell apoptosis. Cancer Res. 59:5412–5416. 1999.PubMed/NCBI
|
|
36
|
Eguchi M, Masuda H and Asahara T:
Endothelial progenitor cells for postnatal vasculogenesis. Clin Exp
Nephrol. 11:18–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Packard BZ, Artym VV, Komoriya A and
Yamada KM: Direct visualization of protease activity on cells
migrating in three-dimensions. Matrix Biol. 28:3–10. 2009.
View Article : Google Scholar :
|
